ArticleTrials2026
Effect of early intensive physical therapy on NLRP3 inflammasome activation and muscle atrophy in critical illness myopathy (PT-NLRP3-CIM): a two-centre randomized open-label study protocol.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07017517 (Effect of Physical Therapy on NLRP3 Inflammasome Activation and Muscle Atrophy in Critical Illness Myopathy), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Physical Therapy on NLRP3 Inflammasome Activation and Muscle Atrophy in Critical Illness Myopathy (PT-NLRP3-CIM).
Who cites it
1 citing paper in PubMed.
- Muscle Dysfunction in Critical Illness: Established Mechanisms and the Potential Contribution of the NLRP3 Inflammasome.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCritical illness myopathy (CIM) is a prevalent cause of intensive care unit-acquired weakness (ICUAW). It is associated with prolonged mechanical ventilation and increased mortality and frequently evolves into postintensive care syndrome with long-term cognitive and physical impairments. Although several molecular mechanisms have been implicated in CIM, including muscle atrophy and altered contractility, its exact etiopathogenesis is not fully understood. Evidence suggests that activation of the NLRP3 inflammasome and upregulation of atrogenes significantly contribute to this condition. In murine models of sepsis and denervation, which mimic CIM, NLRP3 activation induces muscle atrophy. Physical therapy, including enhanced mobilization supported by servo-assisted devices, a nonpharmacological intervention, can regulate inflammation, reduce IL-1β and NLRP3 levels, and improve mitochondrial and autophagy processes; however, whether it reduces NLRP3 activation and alleviates atrophy in human CIM remains uncertain.
methodsWe will conduct a prospective, randomized, controlled, open-label study during the early ICU stay. Adults at risk of CIM (n = 16) will be randomized 1:1 to conventional physical therapy or to conventional therapy plus enhanced PT (an additional servo-assisted mobilization device, MOTOmed letto DISCUSSION: We hypothesize that enhanced PT (in addition to conventional care) reduces NLRP3 activation and muscle atrophy in critically ill adults. This translational trial combines clinical assessments integrating muscle biopsies and blood measures to elucidate CIM pathogenesis and assess PT intervention. These findings may identify therapeutic targets and inform early mobilization strategies in ICU practice.
trial registrationClinicalTrials.gov NCT07017517. Registered on 26 May 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.